
Noble Capital Markets Initiates Equity Research Coverage on MariMed (MRMD)
Noble Capital Markets Senior Research Analyst Joe Gomes has initiated equity research coverage on MariMed (MRMD) with his report titled "A Cannabis Brands Company; Initiating Coverage"

The Quantum Computing Revolution: Market Implications and Future Impact
Quantum computing, once considered a futuristic concept, is rapidly evolving into a tangible force in the tech industry. Nvidia’s recent announcement of its quantum computing research lab, the Nvidia Accelerated Quantum Research Center (NVAQC), marks a major milestone in the sector.

Noble Capital Markets Initiates Equity Research Coverage on Gyre Therapeutics (GYRE)
Noble Capital Markets has initiated equity research coverage on Gyre Therapeutics (GYRE) with today's report, titled "Initiation of Coverage: Focused On Fibrosis"

Market Volatility and the Rise of Small-Cap Value Stocks
The current market environment is one defined by stark contrasts. On one hand, major indices are faltering, led by a steep sell-off in technology stocks. The NASDAQ-100, once the pillar of market growth, is now in free fall, weighed down by declining FAANG stocks. Investors who previously viewed these stocks as untouchable are now reassessing their portfolios amid shifting economic conditions and concerns over stretched valuations.

The Power of Patient Investing: Small Caps, Big Returns
In a market often dominated by mega-cap tech stocks and headline-grabbing trends, small cap investing remains a powerful avenue for those willing to embrace patience as their primary strategy. While these smaller companies may lack the immediate name recognition of their larger counterparts, they offer distinct advantages to investors who can weather short-term volatility in pursuit of long-term gains.

Noble Capital Markets Initiates Equity Research Coverage on Nutriband (NTRB)
Noble’s Equity Research Analyst Robert LeBoyer launched coverage on Nutriband today with his report titled “Initiating Coverage With An Outperform Rating And $13 Price Target”

How Trump’s DOGE Initiative Could Reshape Biotech’s Future
The Department of Government Efficiency (DOGE), spearheaded by Donald Trump with the involvement of Elon Musk and Vivek Ramaswamy, promises sweeping changes to federal operations, including deregulation efforts targeting agencies like the FDA. For the biotech industry, these potential reforms could significantly impact drug development, approval processes, and market dynamics.

Noble Capital Markets Served as Co-Manager to Eledon Pharmaceuticals (ELDN) in $85mm Follow-on Offering
Eledon transaction main points.

Noble Capital Markets Initiates Equity Research Coverage on Zomedica Corp. (ZOM)
Noble’s Equity Research Analyst Rober LeBoyer launched coverage on Zomedica Corp. today with his report titled "Improving Pet Health and Veterinary Practices - Initiating Coverage With An Outperform Rating"

Noble Capital Markets Initiates Equity Research Coverage on Perfect Corp. (PERF)
Noble’s Equity Research Analyst Patrick McCann launched coverage on Perfect Corp. today with his report titled "An AI Company Positioned to Accelerate Revenue Growth"

Noble Capital Markets Initiates Research Coverage on Steelcase Inc. (SCS)
Noble's Equity Research Analyst Joe Gomes launched coverage on Steelcase Inc. today with his report titled "A Global Leader with Room to Grow"

Noble Capital Markets Initiates Equity Research Coverage on Vince Holding Corp. (VNCE)
Noble’s Equity Research Analyst Michael Kupinski launched coverage on Vince Holding Corp. today with his report titled “Positioning For a Favorable 2025"